Savara (SVRA) Expected to Announce Quarterly Earnings on Thursday

Savara (NASDAQ:SVRA) is expected to issue its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.

Savara Stock Down 6.8 %

Shares of NASDAQ:SVRA opened at $2.32 on Tuesday. Savara has a 52-week low of $2.31 and a 52-week high of $5.70. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The firm has a market capitalization of $398.16 million, a P/E ratio of -5.40 and a beta of 0.63. The stock has a 50 day moving average price of $2.84 and a 200-day moving average price of $3.47.

Analyst Upgrades and Downgrades

SVRA has been the subject of a number of analyst reports. Wells Fargo & Company initiated coverage on Savara in a research report on Friday, December 20th. They set an “overweight” rating and a $8.00 price objective for the company. HC Wainwright reduced their price objective on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research report on Thursday, December 19th. Finally, Evercore ISI reaffirmed an “in-line” rating and set a $5.00 price objective (down previously from $7.00) on shares of Savara in a research report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Savara presently has a consensus rating of “Moderate Buy” and an average price target of $9.86.

Insider Buying and Selling at Savara

In other news, CEO Matthew Pauls sold 54,702 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $3.31, for a total value of $181,063.62. Following the transaction, the chief executive officer now directly owns 1,536,379 shares in the company, valued at $5,085,414.49. This trade represents a 3.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 5.13% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.